|
Efficacy of lifestyle interventions in physical health management of patients with severe mental illnessAbstract: It is well known that patients with severe mental illnesses (SMIs) such as schizophrenia, depression, or bipolar disorder have worse physical health and reduced life expectancy compared to the general population [1-4]. There are data suggesting that patients with SMIs die on average between 13.5 and 32.2 years earlier than the general population. A recent study, using years of potential life lost (YPLL) as a measure of premature mortality showed that the mean YPLL in patients with SMIs was 14.5 compared with 10.3 for the general population [5]. Factors affecting patients with SMIs which contribute to these outcomes include more frequent physical comorbidities as compared to the general population [6], genetic predisposition to certain pathologies [7-9], eating habits and sedentary lifestyles [10,11], high levels of cigarette smoking and drug abuse [12-14], limited access to regular health care services [15,16], and potential adverse events arising during pharmacological treatment [17].Weight gain and metabolism disturbances are among the well documented potential adverse events related to antipsychotic medication. A recently published meta-analysis shows that some second-generation antipsychotics (SGAs), such as olanzapine, lead to substantially more metabolic side effects than other SGAs [18]. The majority of studies used to perform the head-to-head comparisons with olanzapine were less than 1 year in length. Other studies have shown no statistical differences between olanzapine and other antipsychotics (typical and atypical) in weight gain and metabolic disturbances after 1 year of treatment [19-21], although significantly greater weight gain was found in olanzapine compared with risperidone and haloperidol after 3 months of treatment [22]. Regardless, a different pattern of weight gain in olanzapine compared with other antipsychotics is proposed [21].In recent years the importance of physical health in patients with SMI has become increasingly recognized by the m
|